Work

Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis

Year: 2026
Type: article
Study design: Observational Study
Abstract: Importance: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5-DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized. Objective: To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5-DM. Design, Setting, and Participants: This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5-DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures: Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures: Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index. Results: Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5-DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance: The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5-DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5-DM.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: green
OpenAlex ID: W7125598695
FWCI:
Cites: 32
Cited by:
Related to: 9